Skip to content

Denali Therapeutics

US · DNLI #2454 by market cap Listed 2017
18.45 +0.25 +1.37%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Price chart

Pre-market 17.89 -1.70%
After-hours 18.45 0.00%
27.2117.6118.452026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on DNLI?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -9.3% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days D → D

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2849 U.S. stocks StockVane covers.

Last computed: 2026-11-21 14:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall C+

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability D-

How much profit the business keeps from each dollar of sales and capital.

Operating margin -59.5% Better than 9%
Net margin -43.9% Better than 9%
Return on equity -45.7% Better than 10%
Return on invested capital -47.7% Better than 6%
Momentum C

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -26.0% Better than 22%
6-month return -1.0% Better than 54%
12-month return (ex latest month) 3.7% Better than 38%
Distance below 52-week high 32.4% Better than 38%
Financial Health A+

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 9.2x Better than 93%
Debt to assets 3.2% Better than 84%
Free cash flow / net income 580.7% Better than 94%
Analyst View A

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 91.5% Better than 81%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -1.55%
1M -2.54%
3M -26.05%
6M -2.02%
YTD +11.75%
1Y +7.52%
3Y -3.86%
5Y -60.84%

Key statistics

Price & volume

Prev close
18.20
Open
17.97
Day range
17.92 - 18.85
Avg price
18.49
Volume
2.63M
Turnover
48.66M
Amplitude
5.11%
52-week range
15.34 - 27.30

Valuation

P/E
-6.21
P/E (TTM)
-10.73
P/B
3.19
EPS
-2.97
Net profit
-476.06M
Net assets
926.32M

Share structure

Market cap
2.96B
Float cap
2.87B
Shares out
160.29M
Float shares
155.54M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2017-12-08
52-week range 26% of range
15.34 27.30

32.4% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-472.62K net over the window

Short interest

Shares short
14.69M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Denali Therapeutics (DNLI)?

Denali Therapeutics last traded at 18.45. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Denali Therapeutics's market cap?

About 2.96B.

What is the P/E ratio of Denali Therapeutics?

The trailing twelve-month P/E is -10.73. The Valuation tab shows it against the stock's own five-year range.

Does Denali Therapeutics pay a dividend?

Denali Therapeutics does not currently pay a regular dividend.

Is Denali Therapeutics a buy according to analysts?

The consensus of 7 analysts is a Buy rating, with an average 12-month price target of 35.33, which implies 91.5% upside from the current price. This is not investment advice.

What is Denali Therapeutics's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Denali Therapeutics a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 20:02:19 · For reference only, not investment advice and not tailored to your situation.

Denali Therapeutics discussion 0 comments

Add a comment